These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 9120416)

  • 1. Update on management and genetics of multiple sclerosis.
    Sadovnick AD
    J Neural Transm Suppl; 1997; 50():167-72. PubMed ID: 9120416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
    Nikfar S; Rahimi R; Abdollahi M
    Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Newer versus older treatments for relapsing-remitting multiple sclerosis.
    Weinstock-Guttman B; Cohen JA
    Drug Saf; 1996 Feb; 14(2):121-30. PubMed ID: 8852526
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis.
    Petkau J; White R
    Mult Scler; 1997 Dec; 3(6):402. PubMed ID: 9493643
    [No Abstract]   [Full Text] [Related]  

  • 5. Urinary myelin basic protein-like material in patients with multiple sclerosis during interferon beta-1b treatment.
    Whitaker JN; Layton BA; Bartolucci AA; Mitchell GW; Bashir K; Goodwin J; Kachelhofer RD
    Arch Neurol; 1999 Jun; 56(6):687-91. PubMed ID: 10369307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood levels of transforming growth factor-beta 1 (TGF-beta1) are elevated in both relapsing remitting and chronic progressive multiple sclerosis (MS) patients and are further augmented by treatment with interferon-beta 1b (IFN-beta1b).
    Nicoletti F; Di Marco R; Patti F; Reggio E; Nicoletti A; Zaccone P; Stivala F; Meroni PL; Reggio A
    Clin Exp Immunol; 1998 Jul; 113(1):96-9. PubMed ID: 9697990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparing the cost-effectiveness of disease-modifying drugs for the first-line treatment of relapsing-remitting multiple sclerosis.
    Goldberg LD; Edwards NC; Fincher C; Doan QV; Al-Sabbagh A; Meletiche DM
    J Manag Care Pharm; 2009 Sep; 15(7):543-55. PubMed ID: 19739877
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon beta-1b for the treatment of multiple sclerosis.
    Petri T; Weber-Diehl F
    J Biotechnol; 1995 Nov; 43(1):74-5. PubMed ID: 8573325
    [No Abstract]   [Full Text] [Related]  

  • 9. Interferon-beta-1b: a review of its use in relapsing-remitting and secondary progressive multiple sclerosis.
    McCormack PL; Scott LJ
    CNS Drugs; 2004; 18(8):521-46. PubMed ID: 15182221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emotional state of patients with relapsing-remitting MS treated with interferon beta-1b.
    Borràs C; Río J; Porcel J; Barrios M; Tintoré M; Montalban X
    Neurology; 1999 May; 52(8):1636-9. PubMed ID: 10331691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon beta for multiple sclerosis.
    Connelly JF
    Ann Pharmacother; 1994 May; 28(5):610-6. PubMed ID: 8069001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon beta-1b inhibits reactive oxygen species production in peripheral blood monocytes of patients with relapsing-remitting multiple sclerosis.
    Lucas M; Sánchez-Soliño O; Solano F; Izquierdo G
    Neurochem Int; 1998 Aug; 33(2):101-2. PubMed ID: 9761453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spotlight on Interferon-beta-1b in relapsing-remitting and secondary progressive multiple sclerosis.
    McCormack PL; Scott LJ
    BioDrugs; 2004; 18(5):343-7. PubMed ID: 15377176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The quality-of-life effects of interferon beta-1b in multiple sclerosis. An extended Q-TWiST analysis.
    Schwartz CE; Coulthard-Morris L; Cole B; Vollmer T
    Arch Neurol; 1997 Dec; 54(12):1475-80. PubMed ID: 9400356
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon beta-1B--hope or hype?
    Drug Ther Bull; 1996 Feb; 34(2):9-11. PubMed ID: 8819985
    [No Abstract]   [Full Text] [Related]  

  • 16. Side effect profile of interferon beta-1b in MS: results of an open label trial.
    Neilley LK; Goodin DS; Goodkin DE; Hauser SL
    Neurology; 1996 Feb; 46(2):552-4. PubMed ID: 8614531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data.
    Bell C; Graham J; Earnshaw S; Oleen-Burkey M; Castelli-Haley J; Johnson K
    J Manag Care Pharm; 2007 Apr; 13(3):245-61. PubMed ID: 17407391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon beta-1b.
    Goodkin DE
    Lancet; 1994 Oct; 344(8929):1057-60. PubMed ID: 7934448
    [No Abstract]   [Full Text] [Related]  

  • 19. Nursing management of MS patients receiving interferon beta-1b therapy.
    Costello K; Conway K
    Rehabil Nurs; 1997; 22(2):62-6, 81. PubMed ID: 9110845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
    Lancet; 1998 Nov; 352(9139):1498-504. PubMed ID: 9820297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.